The Department of Biochemistry and Molecular Biology, Institute of Biomedicine, University of Barcelona, Diagonal 645, 08028 Barcelona, Spain.
Pharmacogenomics. 2010 Jun;11(6):809-41. doi: 10.2217/pgs.10.70.
This article focuses on the different types of transporter proteins that have been implicated in the influx and efflux of nucleoside-derived drugs currently used in the treatment of cancer, viral infections (i.e., AIDS) and other conditions, including autoimmune and inflammatory diseases. Genetic variations in nucleoside-derived drug transporter proteins encoded by the gene families SLC15, SLC22, SLC28, SLC29, ABCB, ABCC and ABCG will be specifically considered. Variants known to affect biological function are summarized, with a particular emphasis on those for which clinical correlations have already been established. Given that relatively little is known regarding the genetic variability of the players involved in determining nucleoside-derived drug bioavailability, it is anticipated that major challenges will be faced in this area of research.
本文重点介绍了目前用于治疗癌症、病毒感染（如艾滋病）和其他疾病（包括自身免疫和炎症性疾病）的核苷衍生药物的入胞和出胞所涉及的不同类型的转运蛋白。本文将特别考虑由基因家族 SLC15、SLC22、SLC28、SLC29、ABCB、ABCC 和 ABCG 编码的核苷衍生药物转运蛋白的基因变异。总结了已知影响生物学功能的变异体，特别强调了那些已经建立了临床相关性的变异体。由于参与确定核苷衍生药物生物利用度的参与者的遗传变异性相对知之甚少，可以预期在这一研究领域将面临重大挑战。
